Capricor Announces Initiation of HOPE-2 Clinical Trial of CAP-1002 for Duchenne Muscular Dystrophy
April 30, 2018 07:00 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, April 30, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ:CAPR) today announced it has initiated the HOPE-2 clinical trial at UC Davis Medical Center. The trial will test...